Edition:
United Kingdom

Ludwig Burger

GSK kicks off sale of $1.2 billion consumer health drugs - sources

6:30pm BST

LONDON GlaxoSmithKline (GSK) has kicked off the sale of some consumer health brands as it seeks to raise about £1 billion before pressing ahead with a spinoff of its consumer healthcare business, sources told Reuters.

GSK pharma head flags need for speed in high-pressure drug market

17 Jun 2019

LONDON Doing things one at a time in drug development is not a luxury that GlaxoSmithKline can afford any longer, the head of pharmaceuticals at Britain's largest drugmaker told Reuters.

Bayer lotet Glyphosat-Alternativen aus - verspricht Besserung

14 Jun 2019

Frankfurt Nach Manager-Schelte, Kursverfall und einer Klagewelle in den USA versucht Bayer, wieder in die Offensive zu kommen:

Bayer to invest $5.6 billion in weedkiller research to help reputation

14 Jun 2019

FRANKFURT Germany's Bayer sought to repair its reputation on Friday after damage caused by U.S. litigation over claims its glyphosate pesticide causes cancer, saying it would invest 5 billion euros ($5.6 billion) in weedkiller research.

GSK signs up gene-editing pioneers in drug discovery alliance

13 Jun 2019

British drugmaker GSK said it has struck a research deal with the early pioneers of a prominent gene-editing technology at the University of California, in a boost to its prospects for developing new drugs.

Fresenius says tighter EU rules could trigger antibiotic shortage

05 Jun 2019

FRANKFURT German drugmaker Fresenius warned that stricter production norms being considered by Europe's drug regulator could compound shortages of a life-saving antibiotic that is used by about 25 million patients globally each year.

Bayer to work with Foundation Medicine on cancer patient screening

29 May 2019

FRANKFURT Bayer announced a collaboration deal with Roche's Foundation Medicine Inc. to develop a test for sequencing tumour genomes to identify patients who can benefit from Bayer's cancer drug hopeful Vitrakvi.

Bayer nears seven-year low after $2 billion award in Roundup trial

14 May 2019

Frankfurt Bayer shares fell by as much as 5 percent on Tuesday after a California couple were awarded more than $2 billion (1.54 billion pounds) in the largest U.S. jury penalty over allegations its Roundup weed killer causes cancer. | Video

World News